A kinetic approach towards understanding substrate interactions and the catalytic mechanism of the serine/threonine protein kinase ERK2: Identifying a potential regulatory role for divalent magnesium

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1697, Issue 1-2, 2004, Pages 81-87

  Waas, William F ^a   Rainey, Mark A ^a   Szafranska, Anna E ^a   Cox, Kari ^a   Dalby, Kevin N ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adenosine triphosphate; ATP; c src tyrosine kinase; CSK; Divalent magnesium; ERK; ERK2; Extracellular signal regulated protein kinase 2; MAP kinase; MAPK; Mitogen activated protein kinase; PNT domain; Pointed domain; Protein docking; Protein kinase; SRC

Indexed keywords

ADENOSINE TRIPHOSPHATE; GROWTH FACTOR; MAGNESIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; PHORBOL ESTER; PROLINE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; SERINE; THREONINE; TRANSCRIPTION FACTOR ETS 1;

CATALYSIS; CONFERENCE PAPER; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; EXPERIMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SERUM FACTOR; SIGNAL TRANSDUCTION; STEADY STATE; STRUCTURE ANALYSIS;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; CATALYSIS; CATIONS, DIVALENT; ENZYME ACTIVATION; HUMANS; KINETICS; MAGNESIUM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 1542358857     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.11.015     Document Type: Conference Paper

References (32)

1. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912.
2. Chen Z., Gibson T.B., Robinson F., Silvestro L., Pearson G., Xu B., Wright A., Vanderbilt C., Cobb M.H. MAP kinases. Chem. Rev. 101:2001;2449-2476.
3. Mercer K.E., Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta. 1653:2003;25-40.
4. Sebolt-Leopold J.S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene. 19:2000;6594-6599.
5. Platanias L.C. Map kinase signaling pathways and hematologic malignancies. Blood. 101:2003;4667-4679.
6. Jacobs D., Glossip D., Xing H., Muslin A.J., Kornfeld K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev. 13:1999;163-175.
7. Prowse C.N., Hagopian J.C., Cobb M.H., Ahn N.G., Lew J. Catalytic reaction pathway for the mitogen-activated protein kinase ERK2. Biochemistry. 39:2000;6258-6266.
8. Chevalier D., Allen B.G. Purification of myelin basic protein from bovine brain. Protein Expr. Purif. 18:2000;229-234.
9. Sanghera J.S., Aebersold R., Morrison H.D., Bures E.J., Pelech S.L. Identification of the sites in myelin basic protein that are phosphorylated by meiosis-activated protein kinase p44mpk. FEBS Lett. 273:1990;223-226.
10. Barsyte-Lovejoy D., Galanis A., Sharrocks A.D. Specificity determinants in MAPK signaling to transcription factors. J. Biol. Chem. 277:2002;9896-9903.
11. Waas W.F., Dalby K.N. Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2. Biochemistry. 42:2003;2960-2970.
12. Waas W.F., Dalby K.N. Transient protein-protein interactions and a random-ordered kinetic mechanism for the phosphorylation of a transcription factor by extracellular-regulated protein kinase 2. J. Biol. Chem. 277:2002;12532-12540.
13. Waas W.F., Rainey M.A., Szafranska A.E., Dalby K.N. Two rate-limiting steps in the kinetic mechanism of the serine/threonine specific protein kinase ERK2: a case of fast phosphorylation followed by fast product release. Biochemistry. 2003;. (in press).
14. Seidel J.J., Graves B.J. An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors. Genes Dev. 16:2002;127-137.
15. Slupsky C.M., Gentile L.N., Donaldson L.W., Mackereth C.D., Seidel J.J., Graves B.J., McIntosh L.P. Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12129-12134.
16. Waas W.F., Dalby K.N. Purification of a model substrate for transcription factor phosphorylation by ERK2. Protein Expr. Purif. 23:2001;191-197.
17. Clark-Lewis I., Sanghera J.S., Pelech S.L. Definition of a consensus sequence for peptide substrate recognition by p44mpk, the meiosis-activated myelin basic protein kinase. J. Biol. Chem. 266:1991;15180-15184.
18. Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 90:1997;859-869.
19. Mansour S.J., Candia J.M., Matsuura J.E., Manning M.C., Ahn N.G. Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. Biochemistry. 35:1996;15529-15536.
20. Madhusudan, Akamine P., Xuong N.H., Taylor S.S. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat. Struct. Biol. 9:2002;273-277.
21. Biondi R.M., Nebreda A.R. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem. J. 372:2003;1-13.
22. Shaffer J., Adams J.A. An ATP-linked structural change in protein kinase A precedes phosphoryl transfer under physiological magnesium concentrations. Biochemistry. 38:1999;5572-5581.
23. Dahnke T., Tsai M.D. Mechanism of adenylate kinase. The conserved aspartates 140 and 141 are important for transition state stabilization instead of substrate-induced conformational changes. J. Biol. Chem. 269:1994;8075-8081.
24. Diez-Gonzalez F., Russell J.B., Hunter J.B. The acetate kinase of Clostridum acetobutylicum strain P262. Arch. Microbiol. 166:1996;418-420.
25. Sebastian S., Wilson J.E., Mulichak A., Garavito R.M. Allosteric regulation of type I hexokinase: a site-directed mutational study indicating location of the functional glucose 6-phosphate binding site in the N-terminal half of the enzyme. Arch. Biochem. Biophys. 362:1999;203-210.
26. Adams J.A. Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 101:2001;2271-2290.
27. Hartwig A. Role of magnesium in genomic stability. Mutat. Res. 475:2001;113-121.
28. Saris N.E., Mervaala E., Karppanen H., Khawaja J.A., Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin. Chim. Acta. 294:2000;1-26.
29. Reinhart R.A. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch. Intern. Med. 148:1988;2415-2420.
30. Touyz R.M. Role of magnesium in the pathogenesis of hypertension. Mol. Aspects Med. 24:2003;107-136.
31. Laurant P., Touyz R.M. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J. Hypertens. 18:2000;1177-1191.
32. Paolisso G., Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am. J. Hypertens. 10:1997;346-355.